Compare GCV & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCV | THAR |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.1M | 90.8M |
| IPO Year | N/A | 2022 |
| Metric | GCV | THAR |
|---|---|---|
| Price | $4.34 | $3.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 57.9K | ★ 507.3K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 13.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $0.95 |
| 52 Week High | $4.58 | $9.08 |
| Indicator | GCV | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 55.20 |
| Support Level | $4.32 | $2.71 |
| Resistance Level | $4.39 | $3.05 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 89.69 | 37.06 |
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.